Reneo Pharmaceuticals Inc. (RPHM) Financial Statements (2025 and earlier)

Company Profile

Business Address 6707 WINCHESTER CIRCLE, SUITE 400
BOULDER, CO 80301
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:76,674,00082,835,000102,963,000125,614,000142,677,00093,787,000
Cash and cash equivalents35,970,00020,375,00027,632,00011,737,0009,081,00030,395,000
Short-term investments40,704,00062,460,00075,331,000113,877,000133,596,00063,392,000
Other undisclosed cash, cash equivalents, and short-term investments      
Other undisclosed current assets1,316,0001,092,0003,659,0003,158,0003,643,0003,231,000
Total current assets:77,990,00083,927,000106,622,000128,772,000146,320,00097,018,000
Noncurrent Assets
Operating lease, right-of-use asset493,000546,000599,0001,006,0001,086,0001,188,000
Property, plant and equipment81,000102,000134,000529,000554,000581,000
Other noncurrent assets153,00064,00081,00081,00079,00081,000
Total noncurrent assets:727,000712,000814,0001,616,0001,719,0001,850,000
TOTAL ASSETS:78,717,00084,639,000107,436,000130,388,000148,039,00098,868,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1,017,0002,483,00017,846,00013,238,00013,420,00010,118,000
Accounts payable64,000676,0008,717,0002,473,0001,828,0001,802,000
Accrued liabilities953,0001,807,0009,129,00010,765,00011,592,0008,316,000
Other undisclosed current liabilities331,000331,000331,000325,000318,000363,000
Total current liabilities:1,348,0002,814,00018,177,00013,563,00013,738,00010,481,000
Noncurrent Liabilities
Liabilities, other than long-term debt500,000583,000649,0001,881,0001,773,0001,303,000
Deferred compensation liability, classified 8,0007,0007,0001,069,000876,000324,000
Operating lease, liability492,000576,000642,000812,000897,000979,000
Total noncurrent liabilities:500,000583,000649,0001,881,0001,773,0001,303,000
Total liabilities:1,848,0003,397,00018,826,00015,444,00015,511,00011,784,000
Equity
Equity, attributable to parent76,869,00081,242,00088,610,000114,944,000132,528,00087,084,000
Common stock 3,0003,0003,0003,0003,0003,000
Additional paid in capital309,140,000308,151,000307,073,000305,479,000303,877,000238,859,000
Accumulated other comprehensive income (loss)(13,000)(12,000)8,000(21,000)(31,000)12,000
Accumulated deficit(232,261,000)(226,900,000)(218,474,000)(190,517,000)(171,321,000)(151,790,000)
Total equity:76,869,00081,242,00088,610,000114,944,000132,528,00087,084,000
TOTAL LIABILITIES AND EQUITY:78,717,00084,639,000107,436,000130,388,000148,039,00098,868,000

Income Statement (P&L) (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Operating expenses(6,364,000)(9,564,000)(25,006,000)(20,888,000)(21,039,000)(16,123,000)
Operating loss:(6,364,000)(9,564,000)(25,006,000)(20,888,000)(21,039,000)(16,123,000)
Nonoperating income
(Other Nonoperating income)
1,003,0001,138,0001,452,0001,692,0001,508,0001,016,000
Net loss available to common stockholders, diluted:(5,361,000)(8,426,000)(23,554,000)(19,196,000)(19,531,000)(15,107,000)

Comprehensive Income (USD)

9/30/2024
Q3
6/30/2024
Q2
3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
Net loss:(5,361,000)(8,426,000)(23,554,000)(19,196,000)(19,531,000)(15,107,000)
Other comprehensive income (loss)(1,000)(20,000) 10,000(43,000)55,000
Other undisclosed comprehensive income   51,000   
Comprehensive loss:(5,362,000)(8,446,000)(23,503,000)(19,186,000)(19,574,000)(15,052,000)
Other undisclosed comprehensive loss, net of tax, attributable to parent   (22,000)   
Comprehensive loss, net of tax, attributable to parent:(5,362,000)(8,446,000)(23,525,000)(19,186,000)(19,574,000)(15,052,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: